Bio-Ved Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 2.87 Cr
as on 06-07-2024
- Company Age 29 Year, 4 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.20 Cr
as on 06-07-2024
- Revenue -38.08%
(FY 2020)
- Profit 46.56%
(FY 2020)
- Ebitda 62.65%
(FY 2020)
- Net Worth 10.03%
(FY 2020)
- Total Assets 13.18%
(FY 2020)
About Bio-Ved Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.87 Cr.
The company has closed loans amounting to ₹2.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Deeplaxmi Chitre, Ajit Chitre, and Susheel Sule serve as directors at the Company.
- CIN/LLPIN
U24239MH1995PTC094274
- Company No.
094274
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Nov 1995
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bio-Ved Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Susheel Sule  | Director | 31-Dec-2020 | Current |
Deeplaxmi Chitre  | Director | 08-Nov-1995 | Current |
| Ajit Chitre | Director | 16-Feb-2022 | Current |
Financial Performance and Corporate Structure Insights of Bio-Ved Pharmaceuticals.
Bio-Ved Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 38.08% decrease. The company also saw a substantial improvement in profitability, with a 46.56% increase in profit. The company's net worth Soared by an impressive increase of 10.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-Ved Pharmaceuticals?
In 2019, Bio-Ved Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 26 May 2008 | ₹2.00 M | Satisfied |
How Many Employees Work at Bio-Ved Pharmaceuticals?
Bio-Ved Pharmaceuticals has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-Ved Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-Ved Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
